MIMEDX to Participate at Upcoming Investor Conferences
MIMEDX Group, a leader in regenerative medicine utilizing amniotic tissue, announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MIMEDX Group, a leader in regenerative medicine utilizing amniotic tissue, announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in two upcoming virtual investor conferences. The first event is the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET, and the second is the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 10:00 AM ET. Interested investors can access the webcasts through the company’s website and contact their representatives for meetings.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was -4.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will be participating in the following virtual investor conferences:
- Bank of America Securities 2021 Virtual Health Care Conference
Presentation: Thursday, May 13, 2021 at 2:45 PM ET
Webcast: Click here to access
- Canaccord Genuity Virtual Musculoskeletal Conference
Fireside Chat: Thursday, May 20, 2021 at 10:00 AM ET
Webcast: Click here to access
Institutional investors interested in meeting with management may contact their respective Bank of America or Canaccord Genuity representative.
A live webcast of both presentations will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.
About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.
Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@MIMEDX.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.